| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥26.9B | - | +27.5% |
| Operating Income | ¥2.0B | - | +6.0% |
| Ordinary Income | ¥2.1B | - | +5.1% |
| Net Income | ¥1.3B | - | +18.6% |
| ROE | 16.5% | - | - |
FY2025 consolidated results: Revenue 26.9B yen (YoY +27.5%), Operating Income 2.0B yen (YoY +6.0%), Ordinary Income 2.1B yen (YoY +5.1%), Net Income 1.3B yen (YoY +18.6%). The company achieved simultaneous revenue and profit growth driven by expansion of the Home Visit Nursing Service segment. Gross profit margin remained robust at 43.4%, while operating margin compressed to 7.6% as SG&A expenses reached 9.6B yen. ROE of 16.5% was supported by high asset turnover of 2.0x, though cash conversion lagged with operating CF/net income ratio of 0.55x. Total assets reached 13.5B yen with cash and deposits of 5.9B yen providing strong liquidity. The company executed share buybacks of 0.9B yen while maintaining zero dividend policy.
Revenue expanded 27.5% YoY to 26.9B yen, primarily driven by organic growth in the Home Visit Nursing Service segment and consolidation of subsidiary RePath. The Home Visit Nursing Service segment generated 26.0B yen in revenue (96.5% of total) with operating margin of 29.8%, while the Paramedical Recruitment segment recorded revenue of 0.9B yen with operating loss of 0.3B yen (margin -35.9%). Gross profit increased to 11.7B yen with cost of sales ratio contained at 56.6%. However, SG&A expenses grew to 9.6B yen (35.8% of revenue), including goodwill amortization of 0.1B yen from the RePath acquisition, limiting operating income growth to 6.0%. Non-operating income contributed 0.1B yen (primarily subsidy income of 4.1M yen and interest income of 0.9M yen), lifting ordinary income to 2.1B yen. Income tax expense of 0.8B yen (effective tax rate 38.5%) resulted in net income of 1.3B yen. The performance pattern represents revenue up/profit up with margin compression, as revenue growth of 27.5% significantly outpaced operating income growth of 6.0%, indicating dilutive impact from SG&A leverage and the loss-making Paramedical Recruitment business.
The Home Visit Nursing Service segment is the core business, contributing 96.5% of consolidated revenue at 26.0B yen with operating income of 7.7B yen and segment margin of 29.8%. This segment demonstrated strong profitability anchored by contracts with major customers including Tokyo Metropolitan National Health Insurance Organization Federation (revenue of 16.9B yen). The Paramedical Recruitment segment recorded revenue of 0.9B yen but incurred operating loss of 0.3B yen (margin -35.9%), reflecting startup costs and operational inefficiencies following the RePath consolidation. Corporate costs not allocated to segments amounted to 5.4B yen, primarily general administrative expenses. The 30 percentage point margin differential between segments highlights the significant profit contribution disparity, with the Home Visit Nursing Service segment acting as the primary earnings driver while the Paramedical Recruitment business remains in restructuring phase.
[Profitability] ROE of 16.5% reflects efficient capital utilization supported by asset turnover of 2.0x and financial leverage of 1.74x, though net profit margin of 4.7% indicates room for improvement. Operating margin of 7.6% represents compression from high SG&A burden (35.8% of revenue). Gross margin of 43.4% demonstrates pricing power in the home healthcare service model. [Cash Quality] Cash and deposits of 5.9B yen provide coverage of 1.46x against short-term debt and current liabilities. Operating CF of 0.7B yen generated only 0.55x coverage of net income, flagging earnings quality concerns with cash conversion ratio of 0.34x. Days Sales Outstanding extended to 74 days with trade receivables of 5.5B yen. [Investment Efficiency] Total asset turnover of 2.0x reflects capital-light business model characteristics. Goodwill and intangible assets totaling 0.7B yen represent 5.5% of total assets. [Financial Health] Equity ratio of 57.5% indicates solid capital foundation. Current ratio of 296.3% provides substantial short-term liquidity buffer. Debt-to-equity ratio of 0.18x (interest-bearing debt 1.4B yen versus equity 7.7B yen) and interest coverage ratio of 106x demonstrate minimal financial risk. Net defined benefit liability of 0.3B yen remains manageable.
Operating CF of 0.7B yen represents 0.55x coverage of net income, indicating working capital drag on cash generation. Subtotal operating CF before working capital changes reached 1.4B yen, but trade receivables increased 1.3B yen reflecting revenue growth and extended collection periods (DSO 74 days). Income taxes paid of 0.8B yen consumed significant cash. Investing CF of negative 0.7B yen comprised business acquisition payments of 0.1B yen (RePath consolidation), capital expenditures of 0.1B yen, and lease deposit payments of 0.1B yen, offset partially by lease deposit collections. Financing CF of 0.8B yen reflected long-term loan proceeds of 2.0B yen, loan repayments of 0.2B yen, and share buybacks of 0.9B yen, resulting in net cash increase of 0.8B yen. Free cash flow of approximately 0.0B yen (operating CF minus total investing CF) was neutral, with share buybacks funded through debt financing. Cash position increased 0.8B yen from 5.1B yen to 5.9B yen, though the divergence between reported profits and cash generation warrants monitoring of receivables management and working capital efficiency.
Ordinary income of 2.1B yen versus operating income of 2.0B yen shows modest non-operating net contribution of 0.1B yen, representing less than 1% of revenue and indicating core operations drive profitability with minimal reliance on non-recurring items. Non-operating income totaling 0.1B yen comprises primarily subsidy income of 4.1M yen and interest income of 0.9M yen, both recurring in nature. Extraordinary income of 51K yen from asset disposals is negligible. However, operating CF of 0.7B yen materially underperformed net income of 1.3B yen, with the 0.55x ratio indicating aggressive revenue recognition or working capital deterioration. The primary culprit is trade receivables expansion of 1.3B yen (DSO of 74 days exceeds 60-day benchmark), suggesting extended collection cycles typical of healthcare reimbursement systems but requiring close monitoring. Accrued expenses increased 0.5B yen, partially offsetting receivables drag. With comprehensive income of 1.3B yen matching net income attributable to owners, no material gap exists between accounting earnings and comprehensive earnings, eliminating concerns over unrealized gains or foreign exchange volatility. Overall earnings quality faces pressure from cash conversion dynamics rather than aggressive accounting, pointing to operational execution challenges in working capital management.
Full-year guidance targets revenue of 34.3B yen (YoY +27.5%), operating income of 2.1B yen (YoY +6.0%), and ordinary income of 2.2B yen (YoY +5.1%). Current period progress rates stand at revenue 78.4% and operating income 96.7% against full-year targets, indicating the company is tracking ahead of proportional quarterly phasing (standard Q3 expectation: 75%). Operating income achievement rate of 96.7% versus revenue achievement of 78.4% suggests stronger-than-expected profitability momentum in Q4, though the gap may reflect seasonal patterns or one-time cost controls. The company has not revised guidance, maintaining initial growth assumptions premised on continued Home Visit Nursing Service expansion and operational improvements in the Paramedical Recruitment segment. Forecast notes indicate individual investor briefings scheduled for February 27, 2026, suggesting upcoming strategy updates. Forward visibility is supported by stable customer relationships with healthcare insurance federations, though lack of disclosed order backlog data limits quantitative assessment of pipeline strength.
Annual dividend remains zero yen for both interim and year-end periods, maintaining the no-dividend policy from the prior year. With net income of 1.3B yen and zero dividends, dividend payout ratio is 0%. The company executed share buybacks totaling 0.9B yen during the fiscal year via treasury stock purchases, representing 67.3% of net income and establishing a total return ratio of 67.3% (dividends plus buybacks relative to net income). Treasury stock balance reached 0.1B yen with 83K shares held. The capital allocation strategy prioritizes share buybacks over dividend distributions, returning cash to shareholders through stock repurchases while retaining earnings for growth investments. Operating CF of 0.7B yen covered only 78% of buyback expenditures, with the shortfall funded through long-term borrowings of 2.0B yen. The sustainability of this buyback program depends on improved cash conversion, as current operating cash generation alone is insufficient to support continued repurchases at this scale without reliance on debt financing.
Customer concentration risk is material, with Tokyo Metropolitan National Health Insurance Organization Federation accounting for 16.9B yen or 62.8% of consolidated revenue. Loss of this customer or adverse changes to reimbursement rates would severely impact financial performance. Business segment concentration compounds this risk, as Home Visit Nursing Service represents 96.5% of revenue with limited diversification into the loss-making Paramedical Recruitment business. Working capital management risk manifests in DSO of 74 days and operating CF/net income ratio of 0.55x, creating vulnerability to liquidity stress if receivables collection deteriorates further or revenue growth slows. The company holds trade receivables of 5.5B yen (40.5% of total assets) against cash of 5.9B yen, leaving limited cushion for collection delays. Regulatory and reimbursement risk stems from dependence on Japan's healthcare insurance system, where policy changes to home visit nursing fee schedules, eligibility criteria, or reimbursement timelines could materially affect revenue and margins. Goodwill of 0.7B yen (5.5% of total assets) from the RePath acquisition carries impairment risk if the Paramedical Recruitment segment fails to achieve profitability turnaround.
[Industry Position] (Reference - Proprietary Analysis)
Within the home healthcare and medical staffing services sector, Recovery International demonstrates operational characteristics aligned with capital-light service models while facing execution challenges in cash conversion. The company's ROE of 16.5% reflects efficient asset utilization through high turnover (2.0x) relative to industry norms for healthcare service providers, where asset turnover typically ranges 1.2-1.8x. Operating margin of 7.6% indicates room for improvement compared to industry leaders in home healthcare services that achieve margins of 10-15%, with the gap attributable to high SG&A burden and losses in the Paramedical Recruitment segment. The equity ratio of 57.5% provides conservative financial positioning relative to industry median levels of 40-50% for comparable healthcare service firms. Cash conversion efficiency, as measured by operating CF/net income of 0.55x, lags industry best practices (0.8-1.2x), highlighting relative weakness in working capital management particularly in receivables collection. The company's revenue growth of 27.5% exceeds typical organic growth rates of 5-10% for mature home healthcare operators, suggesting successful market share gains or acquisition-driven expansion. Gross margin of 43.4% aligns with industry norms for labor-intensive healthcare services, while net profit margin of 4.7% trails sector leaders by 3-5 percentage points. The zero dividend policy contrasts with many established healthcare service providers that maintain dividend payout ratios of 30-40%, indicating the company's prioritization of growth investment and share buybacks over income distribution.
Recovery International exhibits strong revenue momentum with 27.5% YoY growth driven by the dominant Home Visit Nursing Service segment, though profitability expansion lags with operating income growing only 6.0%, creating margin compression that warrants attention. The company's business model generates exceptionally high asset turnover of 2.0x translating to ROE of 16.5%, demonstrating efficient capital deployment characteristic of asset-light healthcare service operations. However, a critical structural challenge emerges in cash conversion, where operating CF of 0.7B yen covers only 55% of net income, primarily due to trade receivables expansion to 5.5B yen with DSO extending to 74 days—this divergence between accounting profits and cash generation raises earnings quality concerns and limits self-funded growth capacity. The company maintains strong financial health with equity ratio of 57.5%, current ratio of 296.3%, and minimal leverage (debt-to-equity 0.18x), providing substantial buffer for near-term operational challenges and growth investments. Segment concentration presents both opportunity and risk: the Home Visit Nursing Service segment delivers robust 29.8% operating margin on 96.5% of revenue, while the Paramedical Recruitment business posts 35.9% negative margin, suggesting significant profit upside if turnaround succeeds but downside if restructuring stalls. Customer concentration on Tokyo Metropolitan National Health Insurance Organization Federation (62.8% of revenue) creates dependency risk mitigated only by the essential nature of home healthcare services within Japan's aging demographics. The company's capital allocation strategy favors share buybacks (0.9B yen executed) over dividends (zero payout), funded partially through debt financing given insufficient operating cash flow, indicating management confidence in valuation but raising sustainability questions. Looking forward, key inflection points include narrowing the operating CF-to-net income gap through working capital improvements, achieving profitability in the Paramedical Recruitment segment to reverse margin dilution, and maintaining reimbursement stability amid potential healthcare policy reforms.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.